Earnings Per Share, Diluted of Avalo Therapeutics, Inc. from 31 Dec 2015 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD/shares
Description
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Summary
Avalo Therapeutics, Inc. quarterly and annual Earnings Per Share, Diluted in USD/shares history and change rate from 31 Dec 2015 to 30 Sep 2025.
  • Avalo Therapeutics, Inc. Earnings Per Share, Diluted for the quarter ending 30 Sep 2025 was -2.19, a 23% increase year-over-year.
  • Avalo Therapeutics, Inc. Earnings Per Share, Diluted for the twelve months ending 30 Sep 2025 was 131, a 32% increase year-over-year.
  • Avalo Therapeutics, Inc. annual Earnings Per Share, Diluted for 2024 was -20.91, a 82% increase from 2023.
  • Avalo Therapeutics, Inc. annual Earnings Per Share, Diluted for 2023 was -114.
  • Avalo Therapeutics, Inc. annual Earnings Per Share, Diluted for 2022 was -1,063.
Source SEC data
View on sec.gov
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Change (%)
Earnings Per Share, Diluted, Annual (USD/shares)
Earnings Per Share, Diluted, YoY Annual Change (%)

Avalo Therapeutics, Inc. Quarterly Earnings Per Share, Diluted (USD/shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 131 -2.19 +0.64 +23% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 131 -1.92 +12.15 +86% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 118 -1.25 +140 +99% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 -20 137 -121 -47% 01 Oct 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
Q3 2024 99 -2.83 +24 +89% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 75 -14.07 +127 +90% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 -50 -141 +62.86 +31% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 -113 258 01 Oct 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
Q3 2023 -26.83 -27.17 -7991% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 -141 -139 -10098% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 -204 -202 -8581% 01 Jan 2023 31 Mar 2023 10-Q/A 11 Jul 2024 2024 Q1
Q3 2022 0.34 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 -1.38 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 -2.35 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q3 2018 -0.71 -1.23 -237% 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2018 2018 Q3
Q4 2017 0 -0.11 01 Oct 2017 31 Dec 2017 10-K 02 Apr 2018 2017 FY
Q3 2017 0.52 +1.22 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018 2018 Q3
Q2 2017 -0.14 01 Apr 2017 30 Jun 2017 10-K 02 Apr 2018 2017 FY
Q1 2017 -0.19 01 Jan 2017 31 Mar 2017 10-K 02 Apr 2018 2017 FY
Q3 2016 -0.7 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3

Avalo Therapeutics, Inc. Annual Earnings Per Share, Diluted (USD/shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 -20.91 +92.67 +82% 01 Jan 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
2023 -114 +949 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
2022 -1,063* 01 Jan 2022 31 Dec 2022 10-K 29 Mar 2024 2023 FY
2018 -1.2 -1.62 -386% 01 Jan 2018 31 Dec 2018 10-K 18 Mar 2019 2018 FY
2017 0.42 +2.29 01 Jan 2017 31 Dec 2017 10-K 18 Mar 2019 2018 FY
2016 -1.87 +2.84 +60% 01 Jan 2016 31 Dec 2016 10-K 02 Apr 2018 2017 FY
2015 -4.71 01 Jan 2015 31 Dec 2015 10-K 02 Apr 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.